Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01287546
Title A Study of LY2875358 in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lymphoma

Advanced Solid Tumor

multiple myeloma

Therapies

Emibetuzumab + Erlotinib

Emibetuzumab + Trametinib

Emibetuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.